SMALL CELL LUNG CANCER

This phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This study tested a pill called abemaciclib in 14 people with certain lung cancers (like small cell lung cancer) that stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors and to check its safety. While the drug targets a specific protein to slow…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study looked at 45 patients with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. The goal was to see how long patients went without their cancer getting worse. Because this was a small, single-center review, …

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This study tested a combination of two drugs, anlotinib and penpulimab, in 65 patients with small cell lung cancer whose disease had worsened after initial platinum-based chemotherapy. Anlotinib blocks blood vessel growth to tumors, while penpulimab helps the immune system attack…

This study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if the combination could slow cancer growth better than…

This early-phase study tested a combination of two drugs, tarlatamab and AMG 404, in 23 adults with small cell lung cancer that had worsened after standard chemotherapy. The main goal was to check safety and find the right dose for future studies. Participants had to be in fairly…

This study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if trilaciclib could protect the bone marrow and immune system from chemotherapy damage, reducing severe side effects like low white b…

This study tested whether adding a drug called trilaciclib to standard chemotherapy could protect the bone marrow and immune system in people with advanced small cell lung cancer. About 100 participants received either trilaciclib or a placebo alongside their chemo. The main goal…

This study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…

This study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…

This study looked at whether a new type of PET/CT scan can help predict how well treatment will work for people with a certain type of lung cancer (limited-stage small cell lung cancer). 33 participants had the scan before starting standard treatment. Researchers then tracked the…

This study looked at whether a simple blood test can monitor lung cancer progression without needing to sample the tumor directly. Researchers checked for genetic changes in the blood of 200 lung cancer patients. The goal was to see if this non-invasive method could track how the…